DANVERS, Mass. – Admune Therapeutics LLC ("Admune"), a clinical-stage biotechnology company developing cytokine drugs for cancer immunotherapy, today announces that it has agreed to the sale of Admune to Novartis. The focus of the acquisition is Admune’s lead compound, Heterodimeric IL-15 (IL15:IL15Ra), a novel IL-15 agonist that may have broad applications for cancer immunotherapy. Admune will be integrated into Novartis’ rapidly expanding immune-oncology portfolio.
Admune’s IL-15 agonist is currently in phase I clinical trials for metastatic cancers at the National Cancer Institute of the National Institutes of Health. In pre-clinical studies, IL-15 therapies have been shown to activate lymphocyte cells including CD8+ T-cells and Natural Killer (NK) cells that play a critical role in stimulating the body’s immune system.
"This acquisition by Novartis is a testament to the significant progress our team and lead scientist Dr. George N. Pavlakis have made in more than a decade of researching cytokines for oncology. We are very excited about the future for Admune under the guidance of Novartis, and in particular the potential we believe Admune has for treating cancer patients,” said Sergio Finkielsztein, CEO of Admune Therapeutics.
About Admune Therapeutics
Admune Therapeutics, a clinical stage biotechnology company, was founded by a highly experienced team of scientists and business people with a proven track record in producing successful biomedical products. Admune Therapeutics is affiliated with Marine Polymer Technologies, Inc. (MPT), a provider of groundbreaking medical solutions focused in the areas of hemostasis and wound healing. Admune Therapeutics is engaged in a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to conduct R&D and commercialize innovative cytokine cancer therapies that will benefit human health. For more information, visit http://admune.com/